Life sciences and electronic business driven by dual engines, Merck Germany's Q2 beats expectations and raises full-year profit guidance.

Thanks to the strengthening performance of its laboratory equipment and electronics business, Merck KGaA, the German group, released better-than-expected second-quarter financial results on Thursday and raised its profit and sales guidance for the year. The company expects adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) for the year to reach 5.9 billion to 6.3 billion (approximately $6.8 billion to $7.3 billion), up from the previous guidance of 5.7 billion to 6.1 billion. The upper limit of the annual net sales forecast was adjusted upwards to 21.8 billion, previously set at 21.4 billion. The German technology and healthcare group attributed the upgrade in performance to the strengthened momentum in its life sciences and electronics businesses, while foreign exchange headwinds have eased. New CEO Kai Beckmann is focused on driving comprehensive improvements across the groups three main business segmentsHealthcare, Life Science, and Electronics. This marks the second time he has raised the performance guidance since taking office in May. The largest move to date has been the $11.3 billion acquisition of life sciences company Bio-Techne Corp. Announced in June, this transaction is Mercks largest acquisition since its $17 billion purchase of Sigma-Aldrich in 2014. Merck previously stated that this American companys laboratory proteins and instruments would complement its existing product portfolio and contribute to growth following the completion of the deal. Adjusted EBITDA for the second quarter rose to 1.6 billion, surpassing the average market expectation of 1.5 billion from compiled analysts; revenue for the quarter also exceeded expectations at 5.4 billion. As of Wednesday, Mercks stock price has risen 18% year-to-date, outperforming the nearly flat healthcare sector of the Stoxx Europe 600 Index. By business segment, the largest segment, Life Science Process Solutions (which provides pharmaceutical equipment), reported double-digit growth, continuing its recovery since the post-pandemic destocking phase. Organic sales in Healthcare declined during the quarter, dragged down by competitive pressures from multiple sclerosis drug Mavenclad and cancer drug Bavencio. Mavenclad faced an unfavorable patent ruling in the U.S., with generic drugs entering the market earlier than expected. However, Merck stated on Thursday that it now assumes the drug will not generate sales starting in August, a delay from the previous assumption of May. The smallest segment, Electronics, continues to see strong demand for AI-related chip manufacturing materials. It should be noted that the company is not related to Merck & Co. in the U.S.; although both share a common origin, they have been operating independently since World War I.